StockIQ.techDexCom Inc. (DXCM) Stock Analysis
Free AI-powered analysis and research for DexCom Inc. stock
Sector: Healthcare
DXCM snapshot
Data as of 3 Nov 2026 close. Updated daily.
DexCom Inc. scores 77/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 77% of its 52-week range, up 38.6% over the past year. Latest reported figures show a profit margin of 20.1%, return on equity of 38.5% and revenue growth of +13.1%.
What is driving the score
- RSI Neutral: +5
- Mixed Trend: -2
- MACD Bullish: +8
- High P/E (31.5): -10
- Excellent Profit Margin (20.1%): +10
- Excellent ROE (38.5%): +8
- High P/B (11.42): -5
- Strong Long-term Uptrend: +8
- Strong Momentum (+38.6% over 1 year): +8
- Low Volume (0.2x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full DXCM report
DexCom Inc. (DXCM) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze DXCM Now →📰 Latest Update
Biosensors - Global Strategic Business Report: Secure Share of the $53.7 Billion Market by 2030 as Abbott, Dexcom, Medtronic and Masimo Accelerate Wearable and AI Diagnostics
Tue, November 3, 2026 at 2:41 PM UTC 4 min read
The global biosensors market, valued at US$35.3 billion in 2024, is projected to reach US$53.7 billion by 2030, growing at a CAGR of 7.2%. Key drivers include the demand for chronic disease monitoring, personalized medicine, and advancements in nanotechnology and portable diagnostics. Major companies like Abbott, Dexcom, Medtronic, and Masimo are accelerating developments in wearable and AI diagnostics, while regulatory focus on food and environmental safety is expanding biosensor applications beyond healthcare.